Template:Herpes antiviral treatment: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
====Initial Episode<ref name="a">Workoski KA and Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen and Reports. 2015; 64(3):1-140.</ref><ref>https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf<ref | ====Initial Episode<ref name="a">Workoski KA and Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen and Reports. 2015; 64(3):1-140.</ref><ref>https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf</ref>==== | ||
*[[Acyclovir]] OR | *[[Acyclovir]] OR | ||
**400mg PO q8hrs x 7-10 days | **400mg PO q8hrs x 7-10 days | ||
Latest revision as of 06:54, 14 May 2022
Initial Episode[1][2]
- Acyclovir OR
- 400mg PO q8hrs x 7-10 days
- or 200mg PO 5x/day x 7-10 days
- Valacyclovir 1g PO q12hrs x 7-10 days OR
- Famciclovir 250mg PO q8hrs x 7-10 days
Recurrence[1]
- Acyclovir OR
- 400mg PO q8hrs x 5 days
- or 800mg PO q12hrs x 5 days
- or 800mg PO q8hrs x 2 days
- Valacyclovir OR
- 500mg PO q12hrs x 3 days
- or 1g PO qd x 5 days
- Famciclovir
- 125mg PO q12hrs for 5 days
- or 1g PO q12hrs for 1 day
- or 500mg PO once, followed by 250mg PO q12hrs for 2 days
Suppressive Therapy[1]
- Acyclovir 400mg PO q12hrs daily OR
- Famciclovir 250mg PO q12hrs daily OR
- Valacyclovir 500mg-1g PO daily (500mg may be less effective)
- ↑ 1.0 1.1 1.2 Workoski KA and Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen and Reports. 2015; 64(3):1-140.
- ↑ https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf